Onderneming ReNeuron Group Plc London S.E.
Aandelen
Biotechnologie & Medisch Onderzoek
Vakgebied
Verkoop per activiteit
GBP in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Cell-based Therapies
100,0
%
| 0 | 100,0 % | 1 | 100,0 % | +31,51% |
Verkoop per regio
GBP in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United Kingdom, United States, China and South East Asia
74,3
%
| 0 | 70,5 % | 0 | 74,3 % | +38,73% |
United States
25,7
%
| 0 | 29,5 % | 0 | 25,7 % | +14,29% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
John Hawkins
DFI | Director of Finance/CFO | 58 | 01-10-14 |
Suzanne Hancock
COO | Chief Operating Officer | - | 01-01-17 |
Chief Tech/Sci/R&D Officer | - | 03-03-22 | |
Simon Dew
PRN | Corporate Officer/Principal | - | 01-11-22 |
Shaun Stapleton
LAW | General Counsel | - | 01-08-15 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Martin Walton
BRD | Director/Board Member | 61 | 22-03-22 |
Iain Ross
CHM | Chairman | 71 | 01-07-21 |
Director/Board Member | 61 | 14-07-21 | |
Michael Owen
BRD | Director/Board Member | 73 | 04-12-15 |
John Hawkins
DFI | Director of Finance/CFO | 58 | 01-10-14 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 57 173 760 | 44 745 727 ( 78,26 %) | 0 | 78,26 % |
Bedrijfsgegevens
Sector
Verkoop per regio
Vaira. 1 jan. | Kapi. | |
---|---|---|
+27,63% | 42,68 mld. | |
-3,08% | 42,4 mld. | |
+45,32% | 40,04 mld. | |
-6,20% | 28,31 mld. | |
+6,80% | 24,94 mld. | |
-21,20% | 18,96 mld. | |
+28,54% | 12,3 mld. | |
-2,48% | 11,95 mld. | |
-1,79% | 11,55 mld. |